Interferon regulatory factors (IRFs) are a family of transcription factors comprising 9 members (IRF1-9) in mammalian cells. They were initially found to play an essential role in modulating the expression of type I interferons (IFN-α and -β), 12 but recent studies have indicated that IRFs also play critical roles in antiviral defense, immune response, hematopoietic development, cell growth/apoptosis, cardiac remodeling, and oncogenesis. [13] [14] [15] Among the 9 family members, IRF7 binds to the DNA consensus sequence GAAWNYGAAANY widely existing in genes, 16 which indicates that IRF7 may modulate a more diverse range of target genes. In fact, a recent study by Honda et al 17 has described IRF7 as a master transcription factor in the regulation of type I IFN-dependent immune responses, suggesting its crucial role in maintaining cellular homeostasis. Furthermore, Barnes et al 18 reported that IRF7 overexpression in B-lymphoblastoid cells resulted in an altered transcriptional profile of cellular genes. Notably, IRF7 can function as a transcriptional activator or a repressor, depending on the cell type and its intrinsic transactivation potential. 19, 20 Accordingly, IRF7 has either oncogenic properties or antitumor effects. For example, IRF7-overexpressing NIH 3T3 (National Institutes of Health 3T3) cells induce tumor formation in nude mice, 21 and overexpression of IRF7 inhibits the growth of MCF-7 (Michigan Cancer Foundation-7) breast cancer cells. 22 However, the role of IRF7 in the process of cardiomyocyte remodeling, particularly in response to chronic pressure overload, has not been investigated. Therefore, we sought to determine the impact of IRF7 deficiency and cardiac-specific IRF7 overexpression on aortic banding (AB)-induced cardiac hypertrophy.
Here, we report that IRF7 acts as novel negative regulator of pathological cardiac hypertrophy through suppression of NFκB signaling. We observed that hypertrophic stress resulted in IRF7 downregulation in both mouse hearts and cardiomyocytes. Moreover, IRF7-deficient mice revealed an aggravated hypertrophic response on chronic AB, whereas the opposite effect occurred in IRF7-overexpressing mice. We also discovered that all regions of IRF7, except for the inhibitory domain (ID: 284-467aa), could interact with the kinase domain (N/1-300aa) of inhibitor of κB kinase-β (IKKβ). Furthermore, blocking NFκB signaling counteracted the effects of IRF7 deficiency, whereas constitutively active IKKβ negated the antihypertrophic effects of IRF7. Taken together, our results reveal a previously unrecognized role for IRF7 in the regulation of cardiac hypertrophy.
Methods
All experiments involving animals were approved by the Animal Care and Use Committee of Renmin Hospital, Wuhan University, China. An expanded Methods section is available in the online-only Data Supplement, which includes Reagents, Mice Used in This Study, 17 Aortic Banding, 1, 8, 9, 15 Echocardiography and Hemodynamic Measurements, 1, 8, 9 Histological Analysis, Cultured Neonatal Rat Cardiac Myocytes and Recombinant Adenoviral Vectors, 1 Measurement of the Protein/DNA Ratio, Atrial Natriuretic Peptide (ANP) Quantification Assays, Immunofluorescence Analysis, Quantitative Real-Time PCR and Western Blotting, 1, 8, 9 IKKβ Activity Assays, Luciferase Reporter Assays, 23, 24 Hydroxyproline Assay, 25 Immunoprecipitation, Glutathione S-transferase (GST) Pull-down Assay, Confocal Microscopy, and Statistical Analysis.
Results

Expression of IRF7 Is Downregulated in Experimental Hypertrophic Models
IRF7 is expressed constitutively in a variety of tissues, including the heart. 26 To determine whether hypertrophic stress can affect IRF7 expression in cardiomyocytes, we first cultured neonatal rat cardiac myocytes (NRCMs) with either Ang II or phenylephrine for 48 hours to induce hypertrophy. Western blotting results revealed that IRF7 protein levels were markedly reduced by 52% (Ang II) and 36% (phenylephrine), respectively. At the same time, we observed a significant increase in 2 hypertrophic markers, β-myosin heavy chain (β-MHC) and ANP ( Figure 1A , n=3 independent experiments, P<0.01 versus PBS), and ANP concentrations in culture medium were also remarkably increased ( Figure S1A in the online-only Data Supplement, P<0.01 versus PBS). Furthermore, in an experimental mouse model with AB-induced cardiac hypertrophy (evidenced by elevation of β-MHC and ANP levels, Figure 1B ), IRF7 expression was downregulated by ≈93% in mouse hearts 4 weeks after AB compared with sham-operated hearts ( Figure 1B , n=3 independent experiments, P<0.01 versus sham). Taken together, these results indicate that hypertrophic stress leads to IRF7 downregulation both in vitro (cardiomyocytes) and in vivo (intact mouse hearts), suggesting that IRF7 has a role in stress-induced cardiac remodeling.
IRF7 Protects Against Angiotensin II-Induced Cardiomyocyte Hypertrophy In Vitro
To define the functional contribution of IRF7 to cardiac hypertrophy, we first performed in vitro studies using primary cultured NRCMs, a well-controlled experimental setting. NRCMs were infected with either AdIRF7 (adenoviral IRF7) to overexpress IRF7 or AdshIRF7 (adenoviral short hairpin IRF7) to knockdown IRF7 ( Figure S1B ) and subsequently exposed to Ang II (1 μM) for 48 hours. The cell surface area was then determined by immunostaining with α-actinin. Notably, under basal conditions neither AdIRF7 nor AdshIRF7 affected the size of cultured NRCMs compared with control AdGFP (adenoviral green fluorescent protein) and AdshRNA (adenoviral short hairpin RNA) cells. However, exposure to Ang II significantly reduced the cell surface area of AdIRF7-infected cells by 29% (Figure 2A and 2B), whereas Ang II-induced cardiomyocyte hypertrophy was enhanced by 62% in AdshIRF7-treated NRCMs compared with controls ( Figure 2A and 2B) . Accordingly, the Ang II-induced expression of hypertrophic hallmarks (ANP and β-MHC) and the ratio of protein/DNA were profoundly suppressed in AdIRF7-infected cardiomyocytes ( Figure 2C and 2D), whereas significantly enhanced in AdshIRF7-infected NRCMs ( Figure 2C and 2D) compared with controls respectively. These results revealed that IRF7 had an antihypertrophic effect on cardiomyocytes.
Overexpression of IRF7 Attenuates Pressure Overload-Induced Cardiac Hypertrophy
We next sought to examine whether increased IRF7 levels in the heart would attenuate the development of cardiac hypertrophy and failure. Thus, we generated a transgenic (TG) mouse model with cardiac-specific IRF7 expression, using the α-MHC promoter (α-MHCp; Figure S2A ). Four germ lines of IRF7-TG mice were created and verified by Western blotting ( Figure  S2B ). At baseline, the IRF7-TG mice displayed normal cardiac morphology and contractile function (Table S1 ). We selected the highest-expressing IRF7 line (TG21) to be used in our experiments. IRF7-TG mice, along with their WT littermates (referred to as NTG), were subjected to AB surgery or a sham operation, and pressure gradients (mm Hg) were equivalent among all AB-operated mice ( Figure S2C ). After 8 weeks of AB, NTG mice developed massive cardiac hypertrophy, as indicated by increased heart weight (HW)/body weight (BW), lung weight (LW)/BW, and HW/tibia length (TL) ratios ( Figure 3A-C) . These changes were accompanied by the following features: (1) thickening of the left ventricular (LV) wall (HE staining, Figure 3D ); (2) increase cardiomyocyte cross-sectional area (WGA [wheat germ agglutinin] staining, Figure 3D and 3E); and (3) upregulation of the hypertrophic markers ANP, B-type natriuretic peptide, and β-MHC ( Figure S2E ). Consistent with this, NTG mice exhibited cardiac dilation and dysfunction 8 weeks after AB, as measured by echocardiographic parameters including LV end-diastolic dimension (LVEDd), LV end-systolic dimension (LVESd), and LV fractional shortening (LVFS; Figure 3F ). Hemodynamic analysis also showed impaired systolic and diastolic functioning of the LV in NTG mice, as determined by the minimum rate of pressure (−dp/dt) and the maximum rate of pressure (+dp/ dt) in LV isovolumetric contraction (Table S2) . However, this pathological cardiac growth, which was induced by chronic pressure overload, was remarkably attenuated in IRF7-TG mice ( Figure 3A -F and Figure S2E ), and the cumulative survival rate of IRF7-TG mice was increased after 8 weeks of AB surgery ( Figure S2D ).
Fibrosis is a classical feature of pathological cardiac hypertrophy and is characterized by the accumulation of collagen in the heart. 27 To further define the effect of IRF7 overexpression on maladaptive cardiac remodeling, we examined the effect of IRF7 on cardiac fibrosis. The extent of fibrosis was quantified by collagen volume through the visualization of the total amount of collagen present in the interstitial and perivascular spaces. We observed that both interstitial and perivascular fibrosis were dramatically increased in NTG hearts that were subjected to AB, but markedly limited in IRF7-TG hearts that experienced the same treatment ( Figure 3G and 3H) . Finally, we measured the synthesis of collagen by analyzing the mRNA expression levels of fibrotic markers (eg, connective tissue growth factor, collagen I, and collagen III; Figure S2F ). Our results consistently revealed a decreased fibrotic response Figure S2F ). Taken together, these data imply that IRF7 overexpression suppressed pressure overload-induced cardiac remodeling.
Ablation of IRF7 Exaggerates Pressure Overload-Induced Hypertrophy
To assess the impact of decreased IRF7 levels on the development of cardiac hypertrophy and failure that are induced by chronic pressure overload, we next used an IRF7 knockout mouse model (IRF7 −/− ), in whom IRF7 expression was absent in the heart ( Figure S3A ). At baseline, IRF7 −/− mice did not show any cardiac abnormalities (Table S1 ). Our preliminary experiments revealed that almost all IRF7 knockout mice died after 8 weeks of AB surgery ( Figure S3C ). Therefore, we subjected IRF7
−/− mice and their wild-type littermates (referred to as IRF7 +/+ ) to AB surgery for 2 weeks, and pressure gradients (mm Hg) were equivalent among all AB-operated mice ( Figure   S3B ). In contrast to IRF7-TG mice, IRF7
−/− mice aggravated AB-induced cardiac hypertrophy, as indicated by greater increases in HW/BW, LW/BW, and HW/TL compared with AB-treated IRF7 +/+ mice ( Figure 4A -C). Histological examination of heart sections also revealed an increased cross-sectional area of cardiomyocytes in the IRF7 −/− mice ( Figure 4D  and 4E ). Consistent with these data, hearts from IRF7 −/− mice showed greater hypertrophic marker induction (ANP, B-type natriuretic peptide, and β-MHC) after 2 weeks of AB compared with controls ( Figure S3D ). Accordingly, IRF7
−/− mice exhibited deteriorated cardiac dilation and dysfunction, as observed through echocardiograph and hemodynamic analysis ( Figure S3E and Table S3 ) and decreased cumulative survival rate ( Figure S3F ). We also assessed the effect of IRF7 deficiency on AB-triggered cardiac fibrosis. Both histological analysis and fibrotic markers analyses consistently demonstrated an increased fibrotic response in AB-operated IRF7 −/− mice compared with AB-treated IRF7 +/+ mice ( Figure 4F and 4G and Figure S3G ). Collectively, these loss-of-function data indicate that ablation of IRF7 exaggerates cardiac hypertrophy and fibrosis in response to chronic pressure overload.
IRF7 Suppresses NFκB Signaling
To gain insight into the molecular mechanisms underlying the negative effects of IRF7 on pathological cardiac hypertrophy, we next sought to identify IRF7-regulated targets using a Cignal This screening kit provides a comprehensive assay for preliminary monitoring of diverse cell signaling pathways by measuring the activities of downstream transcription factors via a dual-luciferase reporter system. The results showed that the activity of NFκB was significantly blocked by IRF7, which was confirmed by performing an NFκB dual-luciferase reporter assay in hypertrophic cardiomyocytes (in vitro) and hearts (in vivo). NRCMs were infected with either AdIRF7 to overexpress IRF7 or AdshIRF7 to knockdown IRF7. Subsequently, these infected cardiomyocytes were exposed to 1 μM of Ang II for 48 hours. Our results showed that compared with controls, Ang II-induced NFκB activation was significantly reduced in the AdIRF7-infected NRCMs but greatly enhanced in the AdshIRF7-infected cardiomyocytes ( Figure 5A ). IRF7 It is known that dimeric NFκB (containing p50, p65, and c-Rel) is inactivated by binding to inhibitors of κB (IκBs), which sequester NFκB in the cytosol in nonstimulated cells. 28 In the classical pathway, the IκB proteins are regulated by kinases, IKKα, and IKKβ. 28 The latter is particularly important because it phosphorylates IκBα at Ser32/36, leading to ubiquitination/degradation of IκBα by the 26S proteasome and subsequent NFκB nuclear entry. 28 It is also clear that IKKβ activation involves phosphorylation at 2 key serine residues (Ser 177/181). Therefore, to elucidate the ways in which IRF7 inhibits NFκB activity, we next examined phosphorylated levels IKKβ and IκBα in hypertrophic cardiomyocytes (in vitro) and hearts (in vivo). In Ang IItreated NRCMs, IRF7 overexpression significantly limited the kinase activity of IKKβ ( Figure S4B ) and activation of IKKβ-IκBα pathway, as evidenced by decreased levels of p-IKKβ Ser181 and p-IκBα Ser32/36 compared with control cells ( Figure 5C ). In line with this, IKKβ-mediated proteosomal degradation of IκBα was attenuated in AdIRF7-myocytes, as indicated by increased levels of total IκBα ( Figure 5C ). Importantly, similar inhibitory effects of IRF7 on the IKKβ-IκBα signaling cascades were also observed in AB-treated IRF7-TG hearts ( Figure 5E ). Using lossof-function strategies, we further demonstrated that decreased IRF7 levels resulted in pronounced activation of IKKβ and IκBα in vitro and in vivo experimental hypertrophic models ( Figure 5D and 5F and Figure S4C ).
Because p65 translocation to the nucleus is important for NFκB activation, 28 we tested the effect of IRF7 on AB-induced p65 nuclear entry via Western blotting. Lamin B was used as a loading control for nuclear extracts. We found that AB-induced phosphorylation of p65 in the nucleus was profoundly attenuated by IRF7 overexpression ( Figure 5G ) and promoted by IRF7 depletion (Figure 5H ), suggesting that IRF7 suppresses p65 nuclear translocation. Collectively, these data indicate that IRF7 negatively regulates the IKKβ-IκBα-NFκB pathway in cardiomyocytes in response to hypertrophic stimuli.
Additionally, given that NFκB activation has been implicated in the regulation of inflammation and apoptosis in many cell types, including cardiac myocytes, 29 we next measured the expression profiles of some NFκB-dependent inflammatory factors (tumor necrosis factor α, monocyte chemotactic protein-1, and interleukin-1β) in animal hearts on chronic AB. Real-time polymerase chain reaction analysis ( Figure  S4D ) and Western blotting ( Figure S4F ) revealed that IRF7 overexpression remarkably blunted AB-induced increases in tumor necrosis factor α, monocyte chemotactic protein-1, and interleukin-1β. Conversely, loss of IRF7 elicited the opposite effect ( Figure S4E and S4G). Terminal deoxynucleotidyl transferase dUTP nick-end labeling analysis and Western blotting showed that the percentage of transferase dUTP nick-end labeling-positive cells, levels of c-Caspase3, and Bax were increased, whereas full-length Caspase3 and Bcl-2 were downregulated in IRF7 knockout mice ( Figure S4I and S4K) . On the contrary, IRF7 overexpression showed the opposite effects on cardiac apoptosis ( Figure S4H and S4J) . These results further support the hypothesis that IRF7 is a novel negative modulator of the NFκB signaling pathway in the hypertrophic hearts.
IRF7 Directly Interacts With IKKβ
Because stress-induced IκBα degradation (and thus NFκB activation) is IKKβ dependent, 29 our finding of IRF7-mediated NFκB inhibition prompted us to examine whether IRF7 directly interacted with IKKβ. We first performed coimmunoprecipitation (IP) experiments in HEK293T (human embryonic kidney 293) cells transfected with FLAG-tagged IKKβ and Myc-tagged IRF7. We found that IRF7 could coprecipitate along with IKKβ and vice versa ( Figure 6A and 5B) which is consistent with the results of co-IP for endogenous proteins in NRCMs ( Figure S5A and S5B). This interaction was further confirmed by the GST-pull-down assay ( Figure 6C ). We next examined the subcellular localization of IRF7 using immunofluorescent staining. We observed that IRF7 and IKKβ were finely colocalized in the cytoplasm of HEK293T cells ( Figure 6D ). Similar results were observed in H9C2 cells ( Figure S5C ). Altogether, these data support that IKKβ can directly interact with and be regulated by IRF7.
To map which regions of IKKβ and IRF7 mediated the interaction, we next generated a series of deletion mutants of IKKβ and IRF7 ( Figure 6E ). Through IP mapping, we found that only the kinase domain (N/1-300aa), located at the N-terminus of IKKβ, was required for the interaction (left, Figure 6E and 6F). However, most regions of IRF7, except for the inhibitory domain (ID: 284-467aa), contributed to IKKβ binding (right, Figure 6E and 6F). Therefore, IRF7 may inhibit IKKβ activity through masking its kinase domain. Importantly, we measured the kinase activity of IKKβ in NRCMs infected with AdIRF7 or AdIRF7-ID (AdGFP as a control). The results showed that overexpression of wild-type IRF7 significantly inhibited the kinase activity of IKKβ, however, overexpression of IRF7-ID (IRF7-inhibitory domain) did not have any effects on its kinase activity ( Figure S5D ).
Inhibitory Role of IRF7 in Pathological Cardiac Hypertrophy Is largely Dependent on the NFκB Signaling Pathway
Next, we examined whether activation or inactivation of the NFκB signaling cascade would affect the regulatory role of IRF7 in the development of pathological cardiac hypertrophy. To address this issue, we generated an inducible mouse model with the cardiac-specific overexpression of IKKβ S177E/S181E
, a constitutively active form of IKKβ ( Figure S6A ). The inducible IKKβ S177E/S181E mice were then mated with IRF7-TG mice to create IRF7/IKKβ S177E/S181E double transgenic mice ( Figure  S6B ). Cardiac overexpression of IKKβ and IRF7 in these animal models was validated by Western blotting ( Figure S6C ). After 4 weeks of AB, the double transgenic mice exhibited a remarkable pathological cardiac hypertrophy, as evidenced by higher HW/ BW, LW/BW, and HW/TL ratios ( Figure S6E -G) compared with AB-operated IRF7-TG mice. Furthermore, histological analysis of hearts from double transgenic mice showed a significant increase in myocyte cross-section and collagen contents compared with AB-operated IRF7-TG mice ( Figure S6D and S6H-J), and cardiac function was also dramatically deteriorated ( Figure S6M ). Additionally, pathological cardiac hypertrophy was remarkably obvious in IKKβ S177E/S181E -TG mice after 4 weeks of AB compared with MEM-Cre controls ( Figure S6D-M) . Taken together, IRF7-elicited inhibitory effects on pathological cardiac remodeling seem to be largely IKKβ dependent.
To further verify the role of the NFκB signaling pathway in the negative effects of IRF7 on cardiac hypertrophy, we overexpressed the nondegradable IκBα super-repressor (IκBα S32A/S36A ) in IRF7 −/− hearts by crossing cardiac-specific IκBα S32A/S36A TG mice with IRF7 −/− mice ( Figure S7A /B). We found that IκBα S32A/S36A significantly reversed the detrimental effects of IRF7 −/− on AB-induced cardiac hypertrophy, as determined by histological analysis and ratios of HW/ BW, LW/BW, and HW/TL (Figure S7C-G) . Moreover, the aggravated effects of IRF7 −/− on fibrotic response and hypertrophic marker induction were dramatically mitigated by IκBα S32A/S36A overexpression ( Figure S7H-K) . Importantly, cardiac function was significantly improved ( Figure S7L) . Collectively, these loss-of-function data confirmed that 
Discussion
In the present study, we used both gain-of-function and loss-offunction approaches to decipher the potential role of IRF7 in pathological cardiac hypertrophy. For the first time, we observed that overexpression of IRF7 in the heart limited chronic pressure overload-induced cardiac remodeling, whereas loss of IRF7 resulted in detrimental effects on the development of pathological cardiac hypertrophy. We also found that the expression levels of IRF7 were significantly reduced in hypertrophic hearts (Figure 1) . Thus, IRF7 upregulation may provide a new therapeutic strategy for the treatment of pathological cardiac hypertrophy.
The mechanisms underlying the negative effects of IRF7 on pathological cardiac remodeling could stem from its direct binding to IKKβ that masks its kinase domain from activation. Except for the inhibitory domain (residues 284-467), which interferes with the binding and transactivation function of IRF7, 30 other regions of IRF7 are responsible for the interaction with IKKβ. One of the regions binding to IKKβ is detected between residues 1 to 246, which contains DNA-binding domain and constitutive activation domain. DNA-binding domain, which specifically binds to IFN-stimulated response element to initiate the transcription of downstream genes, is shared by each member of IRF family and has 5 conserved tryptophan repeats. 30 Constitutive activation domain is located between residues 151 and 246 and possesses constitutive activation activity. 30 Another IKKβ-binding region is found in virus-activated domain and signal response domain of IRF7. Virus-activated domain is an accessory inducibility region on viral infection that is required for increasing basal and virus-inducible activity. 30, 31 Signal response domain is the site of virus-induced phosphorylation, which regulates the transactivation function of IRF7. 32 Only the kinase domain (residues 1-300) of IKKβ interacts with IRF7. IKKβ kinase domain contains several serine residues that can be phosphorylated by upstream kinases, and the phosphorylation is required for activating IKK kinase activity. 33, 34 In our study, IRF7 directly binds to the kinase domain of IKKβ, and then suppresses its phosphorylation level and NFκB signaling. The interaction between IRF7 and IKKβ occurs in the cytoplasm. Hence, besides directly binding to the DNA sequence to modulate target gene expression, IRF7 also functions as a regulator by interacting with other proteins. For instance, it was reported that IRF7 binds to the death domain of MyD88 (myeloid differentiation primary response gene 88) in the cytoplasm to regulate the MyD88-dependent IFN gene expression. 35, 36 Additionally, IRF7 interacts with TRAF6 (tumor necrosis factor receptor associated factor protein 6), a downstream molecule of MyD88, and activates IFN gene transcription, 36 thus our findings further support the notion that IRF7 functions as a critical regulator of IKKβ other than a transcription factor.
On binding to IRF7, the downstream IκB would be inactivated, leading to NFκB retained in the cytosol. In support of this hypothesis, activation of the IKKβ-IκB-NFκB pathway by aortic banding was remarkably limited in IRF7-overexpressing hearts but dramatically aggravated in IRF7-null hearts ( Figure 5E and 5F). Furthermore, restoration of IKKβ activity via overexpression of IKKβ S177E/S181E offset IRF7-induced inhibitory effects on pathological hypertrophy ( Figure S6 ). Our findings clearly indicate that the IKKβ-IκB-NFκB signaling cascade is essential for the development of pathological cardiac hypertrophy. It is known that NFκB is a key regulator of gene expression programs downstream of diverse signal transduction cascades during a variety of physiological and pathophysiological processes, such as inflammation, cardiomyocyte growth, and extracellular matrix remodeling. [37] [38] [39] NFκB also directly interacts with other transcription factors that are involved in the development of cardiac hypertrophy. For example, Liu et al 40 recently demonstrated a direct interaction between transcription factors, nuclear factor of activated T cells and NFκB, which was suggested to integrate these 2 disparate signaling pathways during cardiac hypertrophy.
Nonetheless, there are some controversial reports on the role of NFκB signaling in the regulation of cardiac hypertrophy. Some investigators have shown that NFκB activation is required for the development of cardiac hypertrophy as well as cardiac dysfunction. 40, 41 For example, cardiac-specific NFκB inhibition mediated by expression of a stabilized IκBα mutant attenuates Ang II-induced cardiac hypertrophy. 41 Moreover, cardiac-specific deletion of p65 decreases the hypertrophic response after pressure overload stimulation, reduces the degree of pathological remodeling, and preserves contractile function. 40 In contrast, several additional studies have disputed the importance of NFκB in the regulation of cardiac hypertrophy. 42, 43 For example, Hikoso et al 42 reported that cardio-specific knockdown of IKKβ promoted cardiac hypertrophy, dilation, and dysfunction in response to pressure overload. NFκB inhibition by cardiac-specific deletion of NEMO (NF-kappa B essential modulator), a regulatory subunit of the IKK complex, augmented cardiac hypertrophy and heart failure after AB. 43 In the present study, we observed that the activation of NFκB was inhibited in the hearts with overexpression of IRF7, suggesting that IRF7 may attenuate cardiac remodeling through negative regulation of NFκB signaling. More importantly, inhibition of the NFκB signaling by overexpression of IκBα S32A/ S36A combated the deteriorating effects of IRF7 knockout on cardiac dysfunction and dilation in response to chronic AB, whereas constitutively active IKKβ blocked IRF7-mediated protection from pathological cardiac remodeling. Therefore, the inhibitory effects of IRF7 on cardiac hypertrophy may be largely dependent on inactivation of the NFκB signaling. Our study may add a new molecule to the increasing list that selectively inhibits the activation of transcription factor NFκB in the hypertrophic hearts. Given that NFκB is likely to have multiple divergent effects and may promote or suppress pathogenic processes, future investigation is needed to determine whether IRF7 has a therapeutic potential for the treatment of pathological cardiac hypertrophy.
Given that cardiac hypertrophy is a complicated pathological process that involves multiple molecules, our study cannot rule out other mechanisms that IRF7 is involved. Indeed, as a transcription factor, IRF7 may directly regulate genes related to cardiac hypertrophy. This is actually predicted by the online database. In the present study, we found that IRF7 potentially binds to the regulatory elements of some prohypertrophic and profibrotic genes, such as Myh6, connective tissue growth factor, smad3, smad4, Col11a1, and Col4a2. Therefore, it is likely that IRF7 may have dual roles in regulating cardiac remodeling; however, future work is needed to explore the mechanism by which IRF7 functions as a transcription factor to modulate the development of pathological cardiac hypertrophy. The limitation of this study is that we used global IRF7 knockout to study the roles of IRF7 in the development of cardiac hypertrophy, and a genome-wide gene expression analysis has not been performed. Considering that global knockout of IRF7 may affect other types of cells other than cardiomyocytes in the heart, we used cultured neonatal rat cardiomyocytes in which IRF7 was knocked down by shIRF7. Our results showed that Ang II-caused hypertrophy was enhanced in IRF7-knockdown myocytes, which seems consistent with the findings observed in knockout mice on chronic pressure overload. Additionally, IRF7-TG mice, which overexpressed IRF7 specifically in the heart, showed significant reduction in hypertrophic response. Taken together, both in vivo and in vitro results consistently reflect the importance of IRF7 in the heart to regulate the development of pathological cardiac hypertrophy.
Notably, interferon regulatory factors (IRFs), consisting of 9 members (IRF1-9) in mammals, represent a group of structurally similar transcription factors characterized by having a well-conserved N-terminal DNA-binding domain and a C-terminal IRF association domain. IRFs exert their function either in cooperation or competition with other factors to play an important role in innate immunity, cell cycle, apoptosis, cancer, metabolic diseases, and cardiovascular diseases. 12, 13, 44, 45 Recently, our group intensively reported the role of IRFs in metabolic diseases and cardiovascular diseases.
8,15,46-49 IRF3 and IRF9 alleviate hepatic steatosis and insulin resistance by constraining IKKβ/NFκB signaling or activating PPARa (peroxisome proliferator-activated receptor alpha) target genes, respectively, 46,47 but IRF7 promotes diet-induced obesity and insulin resistance. 48 In cardiovascular system, IRF3 and IRF9 protected against pressure overloadinduced cardiac hypertrophy via suppressing ERK1/2 (extracellular signal-regulated kinases 1/2) or myocardin, respectively, 15, 49 whereas IRF4 aggravated pressure overload-induced hypertrophic response by activating the transcription of cAMP-response element binding protein. 8 In this study, we demonstrate that IRF7 protects against pressure overload-induced cardiac hypertrophy by inhibiting IKKβ/NFκB signaling. Therefore, IRFs have the proper response by regulating an identical yet disparate set of targeted genes, and further studies are needed to clarify how these different IRFs interplay each other in the development of cardiovascular diseases and metabolic diseases.
In conclusion, we have found a novel role for IRF7 in regulating stress-induced cardiac hypertrophy and fibrosis. Importantly, IRF7 serves a protective function during pathological cardiac hypertrophy by inhibiting the IKKβ-IκB-NFκB signaling pathway. These observations provide new insights into the mechanisms of cardiac hypertrophy and may have significant implications for the development of novel strategies for the treatment of pathological cardiac remodeling through targeting IRF7.
Perspectives
By using IRF7 knockout mice and cardiac-specific transgenic mice, we have provided evidences sufficient to demonstrate that IRF7 negatively regulates pressure overload-induced cardiac remodeling via suppressing the IKKβ-IκB-NFκB signaling pathway. These observations suggest that increasing of IRF7 expression could serve as a lead target for the prevention and treatment of cardiac hypertrophy and failure.
What Is New?
• Interferon regulatory factor 7 (IRF7) is downregulated in murine hypertrophic hearts and neonatal rat cardiomyocytes treated with Ang II or phenylephrine.
• IRF7 is a negative regulator of pressure overload-induced cardiac hypertrophy, fibrosis, and cardiac dysfunction.
• IRF7 regulates the development of cardiac hypertrophy via interacting with inhibitor of κB kinase-β and suppressing inhibitor of κB kinase-β-nuclear factor-κB signaling pathway.
What Is Relevant?
• Cardiac remodeling induced by pressure overload is close to what occurs in hypertension.
• The molecular mechanisms of hypertension-induced cardiac remodeling are not elucidated.
• This finding provides additional information for further understanding the effect of IRF family proteins on cardiac remodeling and implications for the development of strategies for the treatment of cardiac remodeling and heart failure.
Summary
The absence of interferon regulatory factor 7 (IRF7) promotes pressure overload-induced cardiac remodeling and dysfunction, whereas cardiac-specific overexpression of IRF7 inhibits the hypertrophic response by interacting with inhibitor of κB kinase-β and then suppressing the inhibitor of κB kinase-β-nuclear factor-κB signaling. Based on the results of the present study, we propose that IRF7 could be considered a therapeutic target for the prevention of cardiac hypertrophy. 
Novelty and Significance
Mice Used in This Study
All experiments involving animals were approved by the Animal Care and Use Committee of Renmin Hospital, Wuhan University. The animal models used for this study are described below.
IRF7 Knockout and Cardiac-Specific IRF7 Overexpressing Mice
Full-length mouse IRF7 cDNA (Origene, MC216147) was cloned downstream of the cardiac α-myosin heavy chain (α-MHC) promoter. The construct was microinjected into fertilized mouse embryos to generate cardiac-specific IRF7 transgenic (TG, C57BL/6J background) mice, the successful generations of these mice were confirmed via PCR analyses of tail genomic DNA using specific forward (5'-ATCTCCCCCATAAGAGTTTGAGTC-3') and the reverse (5'-CCAGACTCGG ATTCCAGTATGTG-3') primers. IRF7 knockout mice (IRF7 -/-, C57BL/6J background, RBRC01420)
were generously provided by Dr Taniguchi Tadatsugu (The University of Tokyo) and shipped by REKEN 1 . IRF7 -/-mice were identified by PCR analysis of tail genomic DNA using primer 1 -Cre/IRF7 Double Transgenic Mice To get the IKKβ S177E/S181E flox mice, we subcloned Flag-tagged, constitutively active, IKKβ S177E/S181E
(Addgene, 11105) into the CAG-CAT-LacZ construct. This construct contains a CMV enhancer and the chicken β-actin gene (CAG) promoter, which are linked to the chloramphenicol acetyltransferase (CAT) gene and flanked by loxP sites. In the transgenic mice, IKKβ S177E/S181E is blocked by the presence of the CAT gene if the CAT sequence is excised by Cre recombinase, IKKβ S177E/S181E is expressed. The IKKβ S177E/S181E flox mice were crossed with α-MHC-MerCreMer transgene mice (MEM-Cre-TG) (Myh6-cre/Esr1, Jackson Laboratory, 005650) to obtain the IKKβ S177E/S181E
-Cre TG mice. For cardiac specific-overexpression of IKKβ S177E/S181E
, tamoxifen (Sigma, T-5648) was injected into 6-week old mice that were positive for the IKKβ S177E/S181E gene that contained MEM-Cre-TG. In particular, 200 mg of tamoxifen was dissolved in 1 ml of ethanol. Approximately 9.0 ml of corn oil (Sigma, C-8267) was added to this solution to attain a final tamoxifen concentration of 20mg/ml. The emulsion was sonicated prior to its injection into mice, and 80 mg/kg/day of the emulsion was injected intraperitoneally (i.p.) daily for 5 consecutive days. IRF7-TG mice were crossed with IKKβ S177E/S181E
-Cre TG mice to produce the IKKβ S177E/S181E
-Cre /IRF7 double transgenic (DTG) mice. MEM-Cre-TG mice were used as controls. The MEM-Cre-TG, IKKβ S177E/S181E -Cre TG and DTG mice were C57BL/6J background. All experiments were performed in male mice with body weights of 24-27g (8 to 10 weeks old).
Aortic Banding
Aortic banding (AB) was performed in accordance with previously described methods [2] [3] [4] [5] . Briefly, mice were anesthetized with pentobarbital sodium (50 mg/kg, i.p.; Sigma). The left chest was opened to identify the thoracic aorta by blunting dissection at the second intercostals space after absence of reflexes was observed. AB was achieved by tying the descending thoracic aorta against a 27G (in mice with body weights of 24-25g) or 26G (in mice with body weights of 25-27g) needle with a 7-0 silk suture, and then removing the needle. In addition, Doppler analysis was performed to ensure that adequate constriction of the aorta had been achieved. Pressure gradients (mmHg) were calculated from the peak blood velocity (Vmax, m/s, PG=4xVmax 2 ) measured by Doppler analyses across the AB, which was equivalent in all groups of AB-operated mice. A similar sham operation was performed, but without aortic constriction.
Echocardiography and Hemodynamic Measurements
Mice were anesthetized by using 1.5-2% isoflurane and echocardiography and hemodynamic measurements were performed at the indicated times in accordance with previously described methods [2] [3] [4] . Cardiac function and structure were determined by echocardiography using a Mylab30CV (ESAOTE) machine with a 15-MHz probe. 2-D M-mode measurements of LV internal diameter were obtained from at least three beats and then averaged. LV end-diastolic dimension 3 (LVEDD) and LV end-systolic dimension (LVESD) were measured at the time of largest and smallest LV areas, respectively. LV fractional shortening (LVFS) was calculated using the following formula: LVFS (%) = (LVEDD-LVESD)/LVEDD×100%. For hemodynamic measurements, a 1.4-French Millar catheter-tip micromanometer catheter (SPR-839; Millar Instruments) was inserted through the right carotid artery into the left ventricle. The pressures and dP/dt were recorded continuously with an Aria pressure-volume conductance system that was coupled with a Powerlab/4SP A/D converter and stored, and displayed on a personal computer.
Histological Analysis
Hearts were excised from anesthetized (pentobarbital sodium; 50 mg/kg, i.p.) mice, fixed for > 24 hours in 10% formalin after being arrested with 10% potassium chloride solution, and then embedded in paraffin. Subsequently, these hearts were sectioned transversely at 5µm. Sections were stained with either hematoxylin-eosin (HE) for histopathology or picrosirius red (PSR) for the collagen deposition. The myocyte cross-sectional area (CSA) was measured with a quantitative digital image analysis system (Image-Pro Plus 6.0) using images that were captured from FITC-conjugated wheat germ agglutinin (WGA, Invitrogen Corp) stained sections. More than 100 myocytes in the examined sections were outlined for each group of mice.
Cultured Neonatal Rat Cardiac Myocytes and Recombinant Adenoviral Vectors
Primary cultures of neonatal rat cardiomyocytes (NRCMs) were prepared in accordance with previously described methods 2 . Briefly, cardiomyocytes from 1-to 2-day-old Sprague-Dawley rats were isolated in phosphate-buffered saline (PBS) containing 0.03% trypsin and 0.04% type II collagenase. After the fibroblasts were removed using a differential attachment technique, NRCMs were seeded at a density of 2×10 5 cells/well onto six-well culture plates coated with gelatin in a plating medium that consisted of DMEM/F12 medium supplemented with 20% FCS, BrdU (0.1 mM, an inhibitor of the proliferation of fibroblasts) and penicillin/streptomycin. After 48 hours, the culture medium was replaced with serum-free DMEM/F12 for 12 hours prior to stimulation with angiotensin II (Ang II, 1 µM) or phenylephrine (PE, 100 µM). To over-express IRF7, the entire coding region of the rat IRF7 gene under the control of the cytomegalovirus promoter was encompassed by replication-defective adenoviral vectors. A similar adenoviral vector encoding the GFP gene was used as a control. To knock-down IRF7 expression, three rat shIRF7 constructs were obtained from SABiosciences (KR54505G), and the construct that produced the most significant decrease in IRF7 levels was selected from three generated AdshIRF7 adenoviruses for further experiments. AdshRNA was used as the non-targeting control. The NRCMs were infected with adenovirus in diluted media at a multiplicity of infection (MOI) of 100 for 24 hours.
Measurement of the Protein/DNA Ratio
For determining total cellular protein and DNA content, NRCMs were washed twice with PBS after stimulated with Ang II or PBS for 48 hours. Then, 0.2N perchloric acid (1 ml) was added to each well. The samples were centrifuged for 10 min at 10,000 g at 4°C. The precipitates were incubated for 20 min at 60 °C with 250 µl of 0.3 N KOH. BCA Protein Assay Kit (Pierce, CAT: 23225) was used to assess protein content, and Hoechst dye 33258 (Invitrogen, CAT: H3569) was used to detect Supplemental Tables   Table S1 . 
